Nathanael McCurley

Company: SIRPant ImmunoTherapeutics

Job title: Co-founder & Vice President - Research & Development

Seminars:

Immunological First Principles: When Unleashed, Macrophages Drive Multimodal Anti-Tumor Responses Without Genetic Modification 3:45 pm

Diminution of SIRPα activity on macrophages promotes neo-antigen-specific polyclonal T cell and antibody responses in adverse environments including the TME Autologous ex-vivo generated macrophages promote anti-tumor effects that cannot be recapitulated with biologics administered to macrophages in vivo A Phase 1 clinical trial will evaluate SIRPant-M™ in patients with relapsed/refractory NHLRead more

day: Day One